Last 48 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.72 | 14.87 | 8.33 | — | 1.74 | 32.33 | 112.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -54.0% | -92.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.03 | 3.09 | 3.04 | 3.69 | 1.05 | 2.62 | 3.02 | 2.77 | 2.96 | 3.36 | 2.92 | 2.82 | 3.23 | 3.87 | 4.03 | 5.71 | 6.74 | 7.73 | 7.49 | 15.06 | 13.35 |
| — | +18.1% | +0.7% | +32.9% | -64.5% | -22.0% | +3.4% | -1.7% | -8.2% | -13.2% | -27.7% | -50.6% | -52.1% | -50.0% | -46.1% | -62.0% | -49.5% | -50.7% | -46.8% | -36.4% | -83.7% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 5.59 | 17.02 | 6.37 | — | 1.55 | 10.36 | 11.98 | — | — | 48.02 | — | — | — | — | — | — | — | — | — | — | — |
| — | +64.3% | -46.8% | — | — | -78.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 14.81 | 7.34 | — | 1.95 | 18.95 | 21.46 | 27.12 | — | 72.38 | 55.58 | — | — | — | — | — | — | — | — | — | — |
| — | -21.8% | -65.8% | — | — | -73.8% | -61.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 6.76 | 14.81 | 7.40 | — | 1.96 | 17.83 | 23.03 | 24.10 | — | 50.90 | 41.27 | — | — | — | — | — | — | — | — | — | 200.32 |
| — | -16.9% | -67.9% | — | — | -65.0% | -44.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8% | 99.1% | 98.2% | -349.5% | 97.6% | 98.4% | 98.3% | 96.9% | 95.3% | 97.2% | 98.4% | 98.6% | 98.2% | 98.7% | 98.8% | 98.6% | 96.9% | 95.2% | 99.6% | 99.5% | 99.1% |
| — | +0.7% | -0.0% | -460.9% | +2.3% | +1.2% | -0.2% | -1.8% | -3.0% | -1.5% | -0.4% | +0.0% | +1.4% | +3.6% | -0.8% | -0.9% | -2.3% | -3.3% | +0.3% | +44.4% | +1.2% | |
| Operating Margin | 39.0% | 29.6% | 45.1% | -448.6% | 64.0% | 18.6% | 18.2% | 14.6% | -3.4% | 6.6% | 8.0% | -15.6% | -45.7% | -13.7% | -25.1% | -41.3% | -58.2% | -23.0% | -53.0% | -100.1% | -110.6% |
| — | +59.3% | +147.4% | -3175.3% | +1968.7% | +182.6% | +127.6% | +193.4% | +92.5% | +147.8% | +131.9% | +62.2% | +21.5% | +40.3% | +52.6% | +58.7% | +47.4% | +78.8% | +10.5% | +62.9% | +91.5% | |
| Net Margin | 30.2% | 21.0% | 35.9% | -461.5% | 60.5% | 8.1% | 3.1% | 0.0% | -20.4% | -12.0% | -11.6% | -38.1% | -66.1% | -41.7% | -91.3% | -77.5% | -89.9% | -56.1% | -89.8% | -148.6% | -37.7% |
| — | +159.9% | +1053.9% | -2097728.6% | +396.8% | +167.5% | +126.9% | +100.1% | +69.2% | +71.2% | +87.3% | +50.8% | +26.5% | +25.7% | -1.7% | +47.8% | -138.6% | +60.9% | -3.9% | +55.9% | +97.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 52.5% | 6.6% | 15.3% | -147.4% | 51.2% | 2.9% | 1.1% | 0.0% | -5.5% | -2.9% | -2.7% | -7.2% | -11.9% | -6.9% | -14.5% | -10.1% | -12.9% | -8.0% | -11.3% | -13.3% | -4.2% |
| — | +131.2% | +1312.6% | -2233848.5% | +1037.7% | +198.0% | +140.3% | +100.1% | +54.0% | +57.6% | +81.4% | +28.6% | +8.0% | +13.7% | -27.8% | +24.3% | -209.9% | +63.3% | +26.3% | +36.0% | +82.4% | |
| ROIC | 104.3% | 59.5% | — | -290.9% | 88.5% | 11.0% | 9.6% | 6.0% | -1.3% | 2.1% | 2.5% | -4.1% | -11.8% | -3.1% | -5.5% | -10.3% | -18.6% | -5.6% | — | -213.2% | — |
| — | +442.5% | — | -4964.4% | +7124.8% | +416.7% | +290.1% | +244.6% | +89.3% | +168.4% | +144.7% | +59.8% | +36.4% | +44.9% | — | +95.2% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 1.28 | 16.58 | 4.14 | — | 1.66 | 22.83 | 23.35 | 38.47 | — | 105.23 | 90.48 | — | — | — | — | — | — | — | — | — | — |
| — | -27.4% | -82.3% | — | — | -78.3% | -74.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.06 | 2.71 | 2.32 | 1.91 | 2.06 | 1.87 | 2.25 | 2.93 | 2.63 | 2.78 | 2.82 | 3.73 | 3.31 | 5.54 | 5.47 | 5.76 | 4.90 | 6.23 | 5.19 | 6.32 | 5.46 |
| — | +45.1% | +3.2% | -34.8% | -21.6% | -32.8% | -20.1% | -21.4% | -20.4% | -49.8% | -48.5% | -35.3% | -32.4% | -11.2% | +5.4% | -8.7% | -10.3% | +229.6% | +125.6% | +133.5% | +78.1% | |
| Quick Ratio | 2.03 | 2.64 | 2.29 | 1.88 | 2.03 | 1.84 | 2.22 | 2.88 | 2.58 | 2.73 | 2.78 | 3.48 | 3.12 | 5.21 | 5.18 | 5.44 | 4.63 | 5.90 | 4.94 | 6.12 | 5.31 |
| — | +43.4% | +3.2% | -34.7% | -21.2% | -32.6% | -20.2% | -17.2% | -17.2% | -47.6% | -46.3% | -36.1% | -32.8% | -11.8% | +4.7% | -11.0% | -12.7% | +229.9% | +123.2% | +130.4% | +77.0% | |
| Interest Coverage | 4.39 | 2.36 | 4.52 | -35.44 | 18.55 | 1.62 | 1.30 | 1.03 | -0.06 | 0.46 | 0.49 | -0.43 | -1.57 | -0.31 | -1.58 | -0.92 | -1.70 | -0.65 | -1.41 | -2.10 | 0.17 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCRX stock.
BioCryst Pharmaceuticals, Inc.'s current P/E is -5.7x. The average P/E over the last 3 quarters is 8.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioCryst Pharmaceuticals, Inc.'s current operating margin is 39.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioCryst Pharmaceuticals, Inc.'s business trajectory between earnings reports.